MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/10428194.2026.2647950

Медицинская библиотека · Leukemia & lymphoma · 2026

When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred.

Lévy Vincent, Lengline Etienne, Chevret Sylvie

СтатьяПеревод пока не подготовлен

Аннотация

In randomized clinical trials (RCT), treatment effect is often measured using the hazard ratio (HR), with HR < 0.8 being of clinical interest. We hypothesized that absolute measures of effect are more meaningful for both practitioners and patients. We selected all articles in the English literature reporting results of RCTs evaluating targeted therapies in chronic lymphocytic leukemia. We digitized the survival curves and computed HR, differences in survival rates and in mean survival times, and net survival benefit by 6 and 12 months. A total of 20 articles were analyzed. All measures were roughly consistent, except the mean survival benefit. For HR < 0.8, 78% of comparisons showed a mean benefit of at least 2.5 months while 53% showed a mean benefit of 6 months. These figures dropped to 43% and 7%, respectively when the benefit was measured by OS. We suggest that absolute measures of treatment effect should be reported more systematically.

Для цитирования: Lévy Vincent, Lengline Etienne, Chevret Sylvie. When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred.. Leukemia & lymphoma. 2026. DOI: 10.1080/10428194.2026.2647950.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.